Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes.

The results of the study, presented by Dr. Patricia Grasso, Associate Professor in the Department of Medicine and Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY, examined the uptake profile, serum half-life, and relative bioavailability of [D-Leu-4] OB3 in male Swiss Webster mice comparing peptide delivery by the intranasal and three separate injection routes. Intranasal delivery using the homogeneous aqueous Intravail(R) excipient formulation provided higher bioavailability than that achieved using intraperitoneal, subcutaneous, or intramuscular injection…